Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Active:	Yes
Cancer Type:	Breast Cancer Unknown Primary	NCT ID:	NCT06263543
Trial Phases:	Phase II	Protocol IDs:	2023-MAH-001 (primary) NCI-2025-02384
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Reshma L. Mahtani, D.O.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06263543

Summary

The purpose of this research study is to see if the medication sacituzumab govitecan (SG)
is effective at the currently approved dose and schedule in people who have previously
received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor
positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG
is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is
to determine if SG is still effective specifically in people who have already received
T-DXd.

Treatment Sites in Georgia

Emory Saint Joseph's Hospital
5665 Peachtree Dunwoody Road NE
Atlanta, GA 30342
www.emoryhealthcare.org

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.